The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women *

@article{Egarter1996TheEO,
  title={The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women *},
  author={Christian Egarter and Paul Geurts and Ewald Boschitsch and Paul Speiser and Johannes C. Huber},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
  year={1996},
  volume={75}
}
Background. Two sequential hormone replacement regimens, containing either estradiol valerate plus medroxyprogesterone acetate (E2V/MPA) or conjugated estrogens plus medrogestone (CE/MED). were compared with respect to effects on climacteric symptoms, lipid metabolism, and hemostasis. 
The pharmacokinetics and efficacy of different estrogens are not equivalent.
  • R. Ansbacher
  • Medicine
  • American journal of obstetrics and gynecology
  • 2001
TLDR
The studies comparing estrogen formulations are summarized, the differential effects of various estrogen products that promote postmenopausal health are discussed, and the dosage and route of administration are discussed. Expand
Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
TLDR
Both ERT regimens were very well tolerated and are suitable alternatives for estrogen replacement therapy of postmenopausal women. Expand
Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.
TLDR
Progestogens may have differential effects on VTE risk according to the molecules and therefore represent an important potential determinant of the thrombotic risk among postmenopausal women using estrogens. Expand
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
TLDR
Route of estrogen administration and type of progestogen determined differential effects of HRT on lipid and lipoprotein levels and future work will focus on the interpretation of the clinical significance of these changes. Expand
Lipid profiles in women with and without climacteric symptoms
TLDR
The lipid profiles of women with and without climacteric symptoms were compared and there were no significant differences in basal characteristics between the two groups. Expand
A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone.
TLDR
Among pharmacological options for menopause management, drospirenone may provide certain advantages over other progestogens in its effect on risk factors for cardiovascular disease and, thus, constitutes a useful addition to the menopausal armamentarium. Expand
The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies
  • N. Ács, Z. Vajo, +4 authors B. Szekacs
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2002
TLDR
HRT was associated with changes that could explain the increased rate of venous thrombotic events, and also with some changes that can account for beneficial vascular effects, and surprisingly, the addition of progestins induced favorable changes in many cases. Expand
The role of hormone replacement therapy in the prevention of postmenopausal heart disease.
  • L. Mosca
  • Medicine
  • Archives of internal medicine
  • 2000
TLDR
This article reviews the observational and clinical trial data evaluating the relation between cardiovascular disease and hormone replacement therapy and biological mechanisms of estrogen and the impact of adding progestins are emphasized. Expand
Efectos del estradiol-drospirenona o estradiol-trimegestona sobre los lípidos y lipoproteínas en menopáusicas
TLDR
La administracion de estradiol-trimegestona produce modificaciones en el perfil lipidico, that se pueden considerar beneficiosas al compararlas with las producidas por el estradio-drospirenona luego of 6 meses of uso. Expand
Mood disorders and menopause.
TLDR
It has been suggested that minor psychologic symptoms at menopause orPsychologic symptoms accompanied by vasomotor symptoms warrant a trial of HRT before considering psychotropic medication, and if the psychologic Symptoms do not respond to HRT, are not accompanied by Vasomotor Symptoms, or are clinically severe, antidepressant medication should be considered first or in addition to H RT. Expand
...
1
2
...

References

SHOWING 1-10 OF 65 REFERENCES
Serum lipoprotein effects of conjugated estrogen and a sequential conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women
TLDR
Conjugated equine estrogen monotherapy resulted is significantly increased levels of high-density lipoprotein cholesterol, with significantly decreased total cholesterol, low density lipoproteins, and atherogenic index, and medrogestone caused no attenuation of any of these clinically important lipop protein changes. Expand
Desogestrel in hormone replacement therapy: long‐term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding
TLDR
Three groups of healthy, postmenopausal women, aged 45–54 years, were randomly assigned to one of three groups for 2 years of treatment: 17β‐oestradiol 1·5 mg on days 1–12 and 17 β‐oesophageal progesterone acetate 10mg on days 12–21 (E2V/MPA) or placebo. Expand
METABOLIC AND HORMONAL EFFECTS OF POST-MENOPAUSAL OESTROGEN REPLACEMENT TREATMENT
TLDR
The net effect on the risk of development of ischemic cardiovascular disease due to the change in plasma lipids induced by EE2 is uncertain and the plasma lipid changes during EV therapy might possibly retard the development of atherosclerosis. Expand
A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters.
TLDR
It is noteworthy that the pattern of changes in haemostatic parameters induced by as little as 10 micrograms of EE is the same as seen after the administration of combined oral contraceptives or the substantially higher doses of EE given as adjuvant therapy to men with prostatic carcinoma. Expand
Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review.
TLDR
It appears that many progestogens are capable of diminishing the beneficial changes induced by oestrogens, and the ultimate effect depends on the type and daily dose of both the oestrogen and the progestogen component. Expand
Effect of conjugated estrogens with and without medrogestone: a prospective study.
OBJECTIVE To study the possible changes in serum lipids and lipoproteins during hormone replacement therapy with special emphasis on the possible effects brought about by the progestogen. DESIGNExpand
Lipid metabolic studies in oophorectomised women: effects on serum lipids and lipoproteins of three synthetic progestogens.
TLDR
The nortestosterone derivatives, norethisterone acetate and levonorgestrel, decreased high density lipoprotein cholesterol as well as alpha-lipoproteincholesterol, while the 17-hydroxyprogesterone derivative medroxy Progester one acetate did not. Expand
Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone.
TLDR
D doses and relative biologic activity of 19-norsteroids and 17-hydroxyprogesterone derivatives are more important for their metabolic effects than are qualitative differences and natural progesterone had no apparent influence on high-density lipoprotein cholesterol or its subfractions and may develop into an attractive alternative to synthetic progestogens. Expand
The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.
TLDR
To delineate and compare the effects of perorally administered conjugated estrogens (CE) and transdermally administered estradiol (E2) in doses needed for hormone replacement therapy (HRT) on haemostasis parameters, 23 postmenopausal women were engaged in a study with an open cross-over design. Expand
New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.
TLDR
The combined, simultaneous or successive treatment by means of tamoxifen and medroxyprogesterone was even more successful for these therapeutic purposes compared to monohormonotherapy. Expand
...
1
2
3
4
5
...